Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL650472 dose-ranging trial versus placebo and cilostazol in intermittent claudication
2005-003119-62Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SL65.0472 in arteriosclerosis obliterans and intermittent claudication (IC) (5 arms), sponsored by Sanofi. Primary endpoint: Percent change in initial claudication distance. Started Dec 2005; status: completed.
02
Drugs
SL65.0472
03
Conditions
arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on 2005-003119-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003119-62.